Table
5: Subjective improvement of clinical symptoms
in both treatment arms
|
Clinical symptoms |
(Gem-Ox) No. (%) |
(Gem-Ox-Pem) No. (%) |
P Value |
|
|
Central lung lesions |
||||
|
|
Dyspnea |
1/8 (12.5) |
2/7 (28.6) |
0.37 |
|
Hemoptysis |
1/4 (25) |
2/6 (33.3) |
0.5 |
|
|
Dysphagia |
- |
- |
1 |
|
|
Hoarseness |
- |
1/2 (50) |
1 |
|
|
Peripheral lung lesions |
||||
|
|
Cough |
3/9 (33.3) |
6/12 (50) |
0.26 |
|
Dyspnea |
1/6 (16.7) |
1/6 (16.7) |
0.55 |
|
|
Chest
pain |
1/3 (33.3) |
1/5 (20) |
0.54 |
|
|
Metastases |
||||
|
|
Bony
pains |
1/6 (16.7) |
2/8 (25) |
0.46 |
|
Jaundice |
- |
1/2 (50) |
1 |
|
|
Neurological |
- |
- |
1 |
|
Gem, gemcitabine ; Ox,
oxaliplatin; Pem, pemetrexed